Literature DB >> 11714905

Model for time dependency of cytotoxic effect of CHS 828 in vitro suggests two different mechanisms of action.

S B Hassan1, E Jonsson, R Larsson, M O Karlsson.   

Abstract

CHS 828 is a novel drug belonging to the cyanoguanidines. It has shown promising anticancer activity in many preclinical systems and is currently in early clinical trials. Our aim in this study was to assess the growth inhibitory effect of CHS 828 in comparison with paclitaxel, etoposide, and topotecan as a function of concentration and time. U937 GTB, RPMI 8226/S, MDA 231, primary cells from chronic lymphocytic leukemia, and normal mononuclear cells were exposed to CHS 828 and U937 GTB cells were exposed to paclitaxel, etoposide, and topotecan in 18 concentrations for times ranging from 1 to 72 h. Cell survival was measured after 72-h incubation by using the fluorometric microculture cytotoxicity assay. Nonlinear mixed effect modeling was used to model the concentration-effect curves with a modified Hill equation. Patterns of change of drug potency (IC(50)), slope of the concentration-effect curves, and plateau with time were studied. The log IC(50) for CHS 828 decreased with log time in a sigmoid manner for all cell types tested. Although very steep at short and long incubation, the concentration-effect curves became shallow at intermediate times. The log IC(50) for etoposide and topotecan was decreased with log time in a sigmoid manner. The log IC(50) for paclitaxel decreased linearly with log time. The information obtained from modeling the cytotoxic effect of CHS 828 and changes of IC(50) and slope parameters with exposure time suggests a heterogeneous cell response to CHS 828. This could indicate two distinct mechanisms of induction of cell death.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11714905

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  7 in total

1.  Cell cycle checkpoint models for cellular pharmacology of paclitaxel and platinum drugs.

Authors:  Ardith W El-Kareh; Rachel E Labes; Timothy W Secomb
Journal:  AAPS J       Date:  2008-02-05       Impact factor: 4.009

2.  Pharmacodynamic modeling of chemotherapeutic effects: application of a transit compartment model to characterize methotrexate effects in vitro.

Authors:  Evelyn D Lobo; Joseph P Balthasar
Journal:  AAPS PharmSci       Date:  2002

3.  Antitumor effect of BPR-DC-2, a novel synthetic cyclic cyanoguanidine derivative, involving the inhibition of MDR-1 expression and down-regulation of p-AKT and PARP-1 in lung cancer.

Authors:  Shun-Lai Li; Chia-Hsin Huang; Chih-Chan Lin; Zih-Ning Huang; Jyh-Haur Chern; Hsiao-Yin Lien; Yong-Yi Wu; Chia-Hui Cheng; Chia-Yu Chang; Jiunn-Jye Chuu
Journal:  Invest New Drugs       Date:  2009-12-05       Impact factor: 3.850

4.  Structure-activity relationship analysis of cytotoxic cyanoguanidines: selection of CHS 828 as candidate drug.

Authors:  Henrik Lövborg; Robert Burman; Joachim Gullbo
Journal:  BMC Res Notes       Date:  2009-06-29

5.  A series of alpha-amino acid ester prodrugs of camptothecin: in vitro hydrolysis and A549 human lung carcinoma cell cytotoxicity.

Authors:  Manjeet Deshmukh; Piyun Chao; Hilliard L Kutscher; Dayuan Gao; Patrick J Sinko
Journal:  J Med Chem       Date:  2010-02-11       Impact factor: 7.446

6.  Target enzyme mutations are the molecular basis for resistance towards pharmacological inhibition of nicotinamide phosphoribosyltransferase.

Authors:  Uffe H Olesen; Jakob G Petersen; Antje Garten; Wieland Kiess; Jun Yoshino; Shin-Ichiro Imai; Mette K Christensen; Peter Fristrup; Annemette V Thougaard; Fredrik Björkling; Peter B Jensen; Søren J Nielsen; Maxwell Sehested
Journal:  BMC Cancer       Date:  2010-12-12       Impact factor: 4.430

7.  Regression of orthotopic neuroblastoma in mice by targeting the endothelial and tumor cell compartments.

Authors:  Dieter Fuchs; Rolf Christofferson; Mats Stridsberg; Elin Lindhagen; Faranak Azarbayjani
Journal:  J Transl Med       Date:  2009-03-12       Impact factor: 5.531

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.